Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.

@article{Jiang2013CannabidiolIA,
  title={Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.},
  author={Rongrong Jiang and S. Yamaori and Yasuka Okamoto and I. Yamamoto and Kazuhito Watanabe},
  journal={Drug metabolism and pharmacokinetics},
  year={2013},
  volume={28 4},
  pages={
          332-8
        }
}
The present study investigated the inhibitory effect of cannabidiol (CBD), a major constituent of marijuana, on the catalytic activity of cytochrome P450 2C19 (CYP2C19). (S)-Mephenytoin 4'-hydroxylase activities of human liver microsomes (HLMs) and recombinant CYP2C19 were inhibited by CBD in a concentration-dependent manner (IC₅₀ = 8.70 and 2.51 µM, respectively). Omeprazole 5-hydroxylase and 3-O-methylfluorescein O-demethylase activities in recombinant CYP2C19 were also strongly inhibited by… Expand
Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.
TLDR
The results suggest that the pentylresorcinol structure in CBD may have structurally important roles in direct CYP1A1 inhibition, although the whole structure of CBD is required for overall inhibition. Expand
Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.
TLDR
The results suggest that the methylresorcinol structure in CBD may have structurally important roles in the inactivation of CYP1A1. Expand
In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters
APINACA (known as AKB48, N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide), an indazole carboxamide synthetic cannabinoid, has been used worldwide as a new psychoactive substance. Drug abusers takeExpand
Cannabinoids as Potent Inhibitors of Human CYP1 Enzymes
Abstract The three major phytocannabinoids, Δ9-Tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), and cannabinol (CBN), are highly lipophilic compounds, and good substrates of liver microsomalExpand
In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes
TLDR
It is concluded that EAM-2201 has the potential to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes. Expand
In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites
TLDR
In this study, in vitro inhibitory effects of the individual major cannabinoids and metabolites ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), 11-nor-THC-carboxylic acid, and 11-hydroxy- THC on CES1 activity were investigated. Expand
A Specific Probe Substrate for Evaluation of CYP4A11 Activity in Human Tissue Microsomes and a Highly Selective CYP4A11 Inhibitor: Luciferin-4A and Epalrestat
TLDR
Results indicated that luciferin-4A O-demethylase activity is a good CYP4A11 marker of HLMs and HRMs, and that epalrestat is a more selective CYP3A11 inhibitor compared with known CYP 4 inhibitors. Expand
Cannabinoids and Cytochrome P450 Interactions.
TLDR
The interplay of central cannabinoid receptors with numerous nervous systems, resulting in a hormone-mediated signal towards nuclear receptors in hepatocytes is hypothesized. Expand
Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites.
The UDP-glucuronosyltransferase (UGT) family of enzymes play a central role in the metabolism and detoxification of a wide range of endogenous and exogenous compounds. UGTs exhibit a high degree ofExpand
Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450
TLDR
A combined (reversible inhibition and TDI) mechanistic static model populated with these data predicted a moderate to strong pharmacokinetic interaction risk between orally administered CBD and drugs extensively metabolized by CYP1A2/ 2C9/2C19/2D6/3A and between orallyadministered THC and drugs extensive metabolizedBy CYP 1A2 /2C9 /3A. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
TLDR
CBD most potently inhibited catalytic activity of human CYP3A enzymes, especially CYP1A4 and CYP2A5, and these results suggest that two phenolic hydroxyl groups in the resorcinol moiety of CBD may play an important role in the CYP 3A inhibition. Expand
Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids
Inhibitory effects of Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), and cannabinol (CBN) on the catalytic activities of human recombinant cytochrome P450 (CYP) 2A6 and CYP2B6 wereExpand
Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
TLDR
Results indicated that CBD and CBN showed CYP1 isoform-selective direct inhibition and that CBD was characterized as a potent mechanism-based inhibitor of human CyP1 enzymes, especially CYP 1A1. Expand
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
TLDR
The results indicated that CBD caused potent direct CYP2D6 inhibition, in which two phenolic hydroxyl groups and the pentyl side chain of CBD may play important roles. Expand
Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
TLDR
NBPB can be used as a potent and selective inhibitor to establish the relative contribution of CYP2C19 for in vitro reaction phenotyping studies and can also serve as a positive control inhibitor of CY P450 reversible inhibition when human liver microsomes are used as the enzyme source. Expand
Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
TLDR
The present study provides the first direct confirmation, using human recombinant P450 enzymes and selective antibody inhibition, that CYP2C19 is a major high affinity OP 5-Hydroxylase and CYP3A4 is a low affinity OP-hydroxylating enzyme. Expand
Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
TLDR
The results indicated that the three major phytocannabinoids but not PAHs contained in marijuana smoke potently inhibited CYP2C9 activity and that these cannabinoids can be characterized as direct inhibitors for CYP 2C9. Expand
Cytochrome P450 Isozymes and Antiepileptic Drug Interactions
  • R. Levy
  • Chemistry, Medicine
  • Epilepsia
  • 1995
Summary: Recent findings about individual isoforms of the cytochromes P450 involved in the metabolism of phe‐nytoin (PHT) and carbamazepine (CBZ) make prediction of inhibition‐based interactionsExpand
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
TLDR
In vitro metabolism of CBD with human liver microsomes indicated that CBD was extensively metabolized by HLMs, and suggested that CYP3A4 and CYP2C19 may be major isoforms responsible for 6α-, 6β-, 7-, and/or 4″-hydroxylations of CBD in HLMs. Expand
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
TLDR
In vitro studies suggest that lansoprazoles and pantoprazole are the most potent in vitro inhibitors of CYP2C19 and CYP3A4, respectively. Expand
...
1
2
3
4
5
...